共 93 条
[1]
Druker BJ(1996)Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561-566
[2]
Tamura S(2001)Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Eng J Med 344 1031-1037
[3]
Buchdunger E(2003)Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Eng J Med 348 994-1004
[4]
Ohno S(2002)Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Eng J Med 346 645-652
[5]
Segal GM(2008)Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 3358-3363
[6]
Fanning S(2002)Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 1928-1937
[7]
Druker BJ(2002)Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530-3539
[8]
Talpaz M(2004)Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study Int J Hematol 80 261-266
[9]
Resta DJ(2006)Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Eng J Med 355 2408-2417
[10]
Peng B(2007)Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in Nagasaki prefecture, Japan Int J Hematol 85 132-139